The Future of HIV-1 Therapeutics

This volume thoroughly covers HIV-1 antiretrovirals currently in clinical use, together with their advantages and limitations. HIV-1 inhibitor resistance is discussed in detail, and critical assessments as to what will be required of future antiretrovirals in order to halt viral replication, reduce viral resistance, and alter the state of viral latency are presented. Experts at the forefront of HIV-1 research provide overviews of approaches from the fields of virology, chemical biology and structural biology for obtaining small molecule inhibitors that target viral regulatory and structural components at multiple points in the viral lifecycle. The individual chapters will appeal to scientists and clinicians alike.

• Fragment-based drug design
• HIV Gag protein
• HIV capsid
• HIV integrase protein
• HIV matrix
• HIV nucleocapsid protein
• HIV protease
• HIV reverse transcriptase protein
• HIV stem-loop
• HIV transcription
• HIV-1 antiretroviral treatment
• HIV-1 drug resistance
• HIV-1 illustrations
• HIV-1 latency
• High-throughput virtual screening
• Human immunodeficiency virus
• LEDGF/p75 protein
• Rev protein
• Structure-based drug design
• Tat/TAR/P-TEFb complex
• antibacterial drug resistance

“The book does a fantastic job of addressing new approaches to inhibit HIV-1. … this is a useful book that can be used by researchers, HIV clinicians, and medicinal chemists interested in investigating new molecules for the treatment of HIV-1. It addresses novel areas that have no chemical entities that are FDA approved. There are no books that compete with this one.” (Christopher J. Destache, Doody's Book Reviews, September, 2015)

“This book includes 8 comprehensive, heavily referenced chapters on antiretroviral drug development. … a comprehensive, readable review of a subject that brings together 2 or more decades of molecular virology research and drug development. … the chapters in this book are likely to be, for the next several years, highly useful and popular starting points for learning about new areas in HIV drug development.” (Robert W. Shafer, Clinical Infectious Diseases, September, 2015)

• Departments of Molecular and Experimental Medicine and Immunology and Microbial Science (MEM 131), The Scripps Research Institute, La Jolla, USA

  Bruce E. Torbett

• Department of Integrative Structural and Computational Biology, and RCSB Protein Data Bank, The Scripps Research Institute, La Jolla, USA

  David S. Goodsell

• Department of Pathology, University of California, San Diego, La Jolla, USA

  Douglas D. Richman